Table 1. Patient characteristics by ABCB1 genotype.
| Full sample | rs1045642 (C3435T) | rs2032582 (G2677T/A) | rs1128503 (C1236T) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| |
|
CC |
TC |
TT |
P-value |
GG |
GT/A |
TT |
P-value |
CC |
TC |
TT |
P-value |
| VEN sample (n) | 41 | 8 | 18 | 15 | 9 | 20 | 12 | 9 | 14 | 18 | |||
| Age, mean (s.d.) | 41 (13) | 38 (13) | 41 (13) | 42 (13) | 0.751 | 38 (15) | 41 (10) | 43 (14) | 0.645 | 37 (14) | 42 (12) | 42 (12) | 0.618 |
| Sex, % (n) female | 63 (26) | 50 (4) | 72 (13) | 60 (9) | 0.523 | 44 (4) | 70 (14) | 67 (8) | 0.402 | 56 (5) | 71 (10) | 61 (11) | 0.716 |
| Education, % (n) tertiary | 49 (20) | 43 (3) | 47 (8) | 60 (9) | 0.653 | 50 (4) | 37 (7) | 75 (9) | 0.180 | 38 (3) | 39 (5) | 67 (12) | 0.491 |
| Ethnicity, % (n) European | 73 (30) | 75 (6) | 65 (11) | 87 (13) | 0.359 | 82 (9) | 77 (27) | 67 (6) | 0.718 | 100 (9) | 69 (9) | 67 (12) | 0.142 |
| Baseline HDRS, mean (s.d.) | 24 (3) | 23 (3) | 24 (4) | 24 (3) | 0.816 | 24 (4) | 24 (3) | 25 (3) | 0.729 | 23 (4) | 25 (3) | 24 (4) | 0.341 |
| MDE, mean (s.d.) | 38 (67) | 30 (35) | 50 (82) | 27 (62) | 0.604 | 21 (35) | 45 (77) | 38 (72) | 0.696 | 17 (34) | 39 (77) | 47 (72) | 0.568 |
| CYP2D6 | 0.073 | 0.135 | 0.844 | ||||||||||
| Poor metabolizer, % (n) | 15 (6) | 25 (2) | 11 (2) | 13 (2) | 33 (3) | 0 (0) | 25 (3) | 22 (2) | 14 (2) | 11 (2) | |||
| Intermediate metaboliser, % (n) | 29 (12) | 25 (2) | 11 (2) | 53 (8) | 22 (2) | 35 (7) | 25 (3) | 33 (3) | 21 (3) | 33 (6) | |||
| Extensive metaboliser, % (n) | 54 (22) | 50 (4) | 78 (14) | 27 (4) | 44 (4) | 65 (13) | 42 (5) | 44 (4) | 64 (9) | 50 (9) | |||
| Ultra metabolizer, % (n) | 2 (1) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 6 (1) | |||
| CYPC19 | 0.429 | 0.831 | 0.846 | ||||||||||
| Poor metaboliser, % (n) | 7 (3) | 0 (0) | 6 (1) | 13 (2) | 11 (1) | 5 (1) | 8 (1) | 11 (1) | 7 (1) | 6 (1) | |||
| Intermediate metaboliser, % (n) | 29 (12) | 50 (4) | 33 (6) | 13 (2) | 44 (4) | 25 (5) | 25 (3) | 33 (3) | 21 (3) | 33 (6) | |||
| Extensive metaboliser, % (n) | 61 (25) | 50 (4) | 61 (11) | 67 (10) | 44 (4) | 65 (13) | 67 (8) | 57 (5) | 64 (9) | 61 (11) | |||
| Ultra metabolizer, % (n) | 2 (1) | 0 (0) | 0 (0) | 7 (1) | 0 (0) | 5 (1) | 0 (0) | 0 (0) | 7 (1) | 0 (0) | |||
| 5-HTTLPR | 0.939 | 0.898 | 0.242 | ||||||||||
| Long/long, % (n) | 17 (7) | 25 (2) | 17 (3) | 13 (2) | 22 (2) | 15 (3) | 17 (2) | 33 (3) | 7 (1) | 17 (3) | |||
| Long/short, % (n) | 46 (19) | 38 (3) | 44 (8) | 53 (8) | 56 (5) | 45 (9) | 42 (5) | 44 (4) | 64 (9) | 33 96) | |||
| Short/short, % (n) | 37 (15) | 38 (3) | 39 (7) | 33 (5) | 22 (2) | 40 (8) | 42 (5) | 22 (2) | 29 (40 | 50 (9) | |||
| ESC sample (n) | 57 | 13 | 29 | 15 | 12 | 35 | 9 | 14 | 30 | 13 | |||
| Age, mean (s.d.) | 38 (13) | 36 (14) | 39 (11) | 39 (16) | 0.834 | 39 (13) | 38 (13) | 34 (14) | 0.647 | 41 (16) | 39 (12) | 34 (12) | 0.305 |
| Sex, % (n) female | 60 (34) | 54 (7) | 66 (19) | 53 (8) | 0.655 | 75 (9) | 54 (19) | 67 (6) | 0.413 | 86 (12) | 43 (13) | 69 (9) | 0.021a |
| Education, % (n) tertiary | 58 (33) | 46 (6) | 59 (16) | 79 (11) | 0.267 | 64 (7) | 56 (19) | 75 (6) | 0.806 | 62 (8) | 62 (18) | 58 (7) | 0.427 |
| Ethnicity, % (n) European | 74 (42) | 62 (8) | 79 (22) | 80 (12) | 0.439 | 89 (8) | 63 (12) | 83 (10) | 0.248 | 77 (10) | 83 (25) | 54 (7) | 0.121 |
| Baseline HDRS, mean (s.d.) | 23 (5) | 24 (4) | 24 (5) | 21 (3) | 0.073 | 23 (3) | 23 (5) | 21 (3) | 0.291 | 25 (5) | 23 (5) | 22 (4) | 0.285 |
| MDE, mean (s.d.) | 43 (78) | 49 (74) | 46 (96) | 31 (33) | 0.787 | 104 (138) | 27 (46) | 24 (22) | 0.008a | 67 (122) | 38 (68) | 27 (21) | 0.375 |
| CYP2D6b | 0.709 | 0.381 | 0.533 | ||||||||||
| Poor metabolizer, % (n) | 5 (3) | 0 (0) | 10 (3) | 0 (0) | 17 (2) | 3 (1) | 0 (0) | 14 (2) | 3 (1) | 0 (0) | |||
| Intermediate metabolizer, % (n) | 30 (17) | 31 (4) | 31 (9) | 27 (4) | 42 (5) | 23 (8) | 33 (3) | 36 (5) | 30 (9) | 23 (3) | |||
| Extensive metabolizer, % (n) | 60 (34) | 69 (9) | 52 (15) | 67 (10) | 33 (4) | 69 (24) | 67 (6) | 50 (7) | 57 (17) | 77 (10) | |||
| Ultra metabolizer, % (n) | 4 (2) | 0 (0) | 3 (1) | 7 (1) | 8 (1) | 3 (1) | 0 (0) | 0 (0) | 7 (2) | 0 (0) | |||
| CYPC19 | 0.501 | 0.356 | 0.487 | ||||||||||
| Poor metabolizer, % (n) | 5 (3) | 8 (1) | 3 (1) | 7 (1) | 0 (0) | 3 (1) | 11 (1) | 7 (1) | 3 (1) | 8 (1) | |||
| Intermediate metabolizer, % (n) | 32 (18) | 46 (6) | 31 (9) | 20 (3) | 42 (5) | 29 (10) | 33 (3) | 43 (6) | 30 (9) | 23 (3) | |||
| Extensive metabolizer, % (n) | 61 (35) | 46 (6) | 66 (19) | 67 (10) | 50 (6) | 69 (24) | 56 (5) | 43 (6) | 17 (6) | 69 (9) | |||
| Ultra metabolizer, % (n) | 2 (1) | 0 (0) | 0 (0) | 7 (1) | 8 (1) | 0 (0) | 0 (0) | 7 (1) | 0 (0) | 0 (0) | |||
| 5-HTTLPR | 0.91 | 0.537 | 0.488 | ||||||||||
| Long/long, % (n) | 28 (16) | 23 (3) | 31 (9) | 27 (4) | 25 (3) | 29 (10) | 33 (3) | 36 (5) | 23 (7) | 31 (4) | |||
| Long/short, % (n) | 40 (23) | 46 (6) | 41 (12) | 33 (5) | 58 (7) | 40 (14) | 22 (2) | 36 (5) | 50 (15) | 23 (3) | |||
| Short/short, % (n) | 32 (18) | 31 (4) | 28 (8) | 40 (6) | 17 (2) | 31 (11) | 44 (4) | 29 (4) | 27 (8) | 46 (6) | |||
Abbreviations: ABCB1, ATP-binding cassette family of transporter proteins, subfamily B (MDR/TAP), member 1; ESC, escitalopram; HDRS, 17-item Hamilton Depression Rating Scale; 5-HTTLPR, serotonin-transporter-linked promoter region; MDE, Major Depressive Episode duration; VEN, venlafaxine.
For subjects treated with ESC significant differences between baseline major depressive episodes duration and proportion of female subjects between the different rs2032582 and rs1128503 genotypes was noted.
a
Bold values denote significant difference at P=0.05 level.
b
One subject on ESC CYP2D6 genotyping assay failed.